文献速递血栓与止血

AAV FVIII基因治疗为何尚未获FDA批准?

Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet?
PubMed 文献 · Blood Adv · 2021-01-01

本文讨论AAV载体表达凝血因子VIII(FVIII)的基因治疗在重度血友病A中的前景与挑战。早期临床研究显示AAV5-FVIII有希望,但长期随访发现载体注射后1年起FVIII转基因水平持续下降至第5年,影响可持续性。文章分析FVIII水平下降的潜在机制及早期和晚期独特发现,并指出缺乏大型动物长期临床前研究、载体再给药不可行等因素。

要点

  • AAV5-FVIII基因治疗在重度血友病A中早期数据有希望,但FVIII表达水平从第1年起持续下降至第5年。
  • 缺乏大型动物长期临床前研究,无法断定FVIII水平下降为意外发现。
  • 目前载体再给药不可行,实现一次给药持久表达是影响疾病表型的关键。

核心结论

  • AAV FVIII基因治疗尚未获FDA批准,主要因长期随访显示FVIII转基因水平从第1年起持续下降至第5年,可持续性存疑。

研究设计与样本

  • 本文为综述/评论性文章,讨论AAV5-FVIII在重度血友病A男性患者中的早期临床研究及长期随访结果。

主要发现

  • 长期随访显示载体注射后1年起FVIII转基因水平持续下降至第5年。
  • 缺乏大型动物长期临床前研究,无法确定FVIII水平下降是否意外。
  • 载体制造平台与剂量、短期超生理水平FVIII异位表达可能共同影响转基因表达的可持续性。
  • 目前载体再给药以提升FVIII水平不可行。

临床怎么用

  • 需关注AAV FVIII基因治疗长期随访中FVIII表达水平的持续下降。
  • 实现一次给药持久表达是影响血友病A疾病表型的关键。

局限性

  • 缺乏大型动物长期临床前研究,限制了对FVIII水平下降的预判。
  • 早期阶段研究的额外随访和进行中的3期研究结果尚未提供。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prospect of a clinical strategy using an adeno-associated virus (AAV) vector for expression of therapeutic levels of factor VIII (FVIII) has been highly desirable. This was initially anticipated by promising data from clinical studies on AAV5-FVIII in men with severe hemophilia A. However, long-term follow-up showed a unique efficacy concern on the sustainability and durability derived from a continuous decline in the FVIII transgene levels starting 1 year after vector injection through year 5. Additional follow-up of early-phase studies and outcomes of an ongoing phase 3 study will likely provide evidence on the feasibility of this approach. Here, the potential underlying mechanisms of the FVIII declining levels, together with the revision of several unique early and late onset findings, are discussed. The lack of long-term preclinical studies in large animal models prevents the firm conclusion that FVIII levels decline was unexpected. It is possible that the combination of vector manufacturing platform and dose, accompanied with ectopic expression of supraphysiologic levels of FVIII at short-term follow-up, may all contribute to the sustainability and durability of the transgene levels. Notably, vector readministration to further improve the FVIII levels is not feasible at this time. Thus, the need of a one-and-done AAV strategy to achieve sustain FVIII levels of expression is sine qua non to impact favorably the disease phenotype.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Arruda VR. Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet? Blood Adv. 2021. PMID: 34698767. doi:10.1182/bloodadvances.2021004760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。